Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.41
PLX's Cash-to-Debt is ranked lower than
90% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. PLX: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
PLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: 0.41
Equity-to-Asset -0.95
PLX's Equity-to-Asset is ranked lower than
97% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PLX: -0.95 )
Ranked among companies with meaningful Equity-to-Asset only.
PLX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.12 Max: 0.8
Current: -0.95
-1.15
0.8
Piotroski F-Score: 2
Altman Z-Score: -7.12
Beneish M-Score: 1.28
WACC vs ROIC
11.26%
-542.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -277.54
PLX's Operating Margin % is ranked lower than
62% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. PLX: -277.54 )
Ranked among companies with meaningful Operating Margin % only.
PLX' s Operating Margin % Range Over the Past 10 Years
Min: -8239.43  Med: -542.39 Max: -35.36
Current: -277.54
-8239.43
-35.36
Net Margin % -700.46
PLX's Net Margin % is ranked lower than
74% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. PLX: -700.46 )
Ranked among companies with meaningful Net Margin % only.
PLX' s Net Margin % Range Over the Past 10 Years
Min: -8103.09  Med: -436.59 Max: 1329.9
Current: -700.46
-8103.09
1329.9
ROA % -102.26
PLX's ROA % is ranked lower than
86% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. PLX: -102.26 )
Ranked among companies with meaningful ROA % only.
PLX' s ROA % Range Over the Past 10 Years
Min: -102.26  Med: -34.11 Max: 66.1
Current: -102.26
-102.26
66.1
ROC (Joel Greenblatt) % -723.10
PLX's ROC (Joel Greenblatt) % is ranked lower than
58% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. PLX: -723.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -988.83  Med: -224.15 Max: -67
Current: -723.1
-988.83
-67
3-Year EBITDA Growth Rate -20.60
PLX's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. PLX: -20.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PLX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: -11.95 Max: 83
Current: -20.6
-53.3
83
3-Year EPS without NRI Growth Rate -8.60
PLX's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. PLX: -8.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -49.3  Med: -7.2 Max: 54.6
Current: -8.6
-49.3
54.6
GuruFocus has detected 2 Warning Signs with Protalix BioTherapeutics Inc $PLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PLX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:CYDY, OTCPK:IMMVF, AMEX:PFNX, NAS:OPHT, NAS:PTI, NAS:CYTR, NAS:ZFGN, OTCPK:HPPI, NAS:ORMP, NAS:AGTC, NAS:VCEL, NAS:CDTX, NAS:CBMG, OTCPK:EGRN, OTCPK:INNMF, NAS:MRTX, OTCPK:IPIX, NAS:ARWR, OTCPK:BBLG, NAS:PRQR » details
Traded in other countries:PBD.Germany, PLX.Israel,
Headquarter Location:Israel
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Protalix BioTherapeutics Inc was originally incorporated in the State of Florida in April 1992. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. Using its ProCellEx system, it is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Its initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company has developed ElelysoTM, its first drug product, ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The Company is now also applying the properties of its ProCellEx system for the oral delivery of therapeutic proteins. The Company relies on a single approved supplier for certain materials relating to the current expression of its proprietary biotherapeutic proteins through ProCellEx. It faces competition from companies with approved treatments of Gaucher disease. Some such companies include iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH. The Company has 94 pending patent applications and one joint pending patent application with a third party. The Company is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.

Top Ranked Articles about Protalix BioTherapeutics Inc

Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference
Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility
Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference
Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
Protalix BioTherapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on May 10, 2017
Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies
Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017

CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. ( MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2016 financial results and provide a corporate update on Thursday, March 16, 2017 at 8:30 am ET.
To participate in the conference call, please dial the following numbers prior to the start of the call: United States: 1-844-358-6760; International: 1-478-219-0004. The conference call will also be broadcast live and available for replay for two weeks on the Company's website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®.  Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner.  Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries.  Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.  Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Investor Contact

Marcy Nanus
The Trout Group, LLC
646-378-2927
[email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 7.71
AMEX:PLX's PS Ratio is ranked higher than
60% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. AMEX:PLX: 7.71 )
Ranked among companies with meaningful PS Ratio only.
AMEX:PLX' s PS Ratio Range Over the Past 10 Years
Min: 3.26  Med: 43.3 Max: 1618
Current: 7.71
3.26
1618
Current Ratio 3.03
AMEX:PLX's Current Ratio is ranked lower than
61% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AMEX:PLX: 3.03 )
Ranked among companies with meaningful Current Ratio only.
AMEX:PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 5 Max: 72.77
Current: 3.03
1.02
72.77
Quick Ratio 2.68
AMEX:PLX's Quick Ratio is ranked lower than
61% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AMEX:PLX: 2.68 )
Ranked among companies with meaningful Quick Ratio only.
AMEX:PLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5 Max: 72.77
Current: 2.68
0.96
72.77
Days Inventory 212.55
AMEX:PLX's Days Inventory is ranked lower than
73% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. AMEX:PLX: 212.55 )
Ranked among companies with meaningful Days Inventory only.
AMEX:PLX' s Days Inventory Range Over the Past 10 Years
Min: 24.15  Med: 207.5 Max: 3304.7
Current: 212.55
24.15
3304.7
Days Sales Outstanding 87.56
AMEX:PLX's Days Sales Outstanding is ranked lower than
64% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. AMEX:PLX: 87.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMEX:PLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.95  Med: 168.97 Max: 2016.91
Current: 87.56
14.95
2016.91
Days Payable 219.78
AMEX:PLX's Days Payable is ranked higher than
85% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. AMEX:PLX: 219.78 )
Ranked among companies with meaningful Days Payable only.
AMEX:PLX' s Days Payable Range Over the Past 10 Years
Min: 174.16  Med: 731.34 Max: 2222.44
Current: 219.78
174.16
2222.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.80
AMEX:PLX's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AMEX:PLX: -9.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMEX:PLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -539.3  Med: -5 Max: 14
Current: -9.8
-539.3
14

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.18
AMEX:PLX's Price-to-Median-PS-Value is ranked higher than
93% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AMEX:PLX: 0.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMEX:PLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.61 Max: 30.09
Current: 0.18
0.01
30.09
Earnings Yield (Greenblatt) % -38.92
AMEX:PLX's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. AMEX:PLX: -38.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMEX:PLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -49.2  Med: -8.3 Max: -2
Current: -38.92
-49.2
-2

More Statistics

Revenue (TTM) (Mil) $11.41
EPS (TTM) $ -0.68
Beta1.18
Short Percentage of Float6.46%
52-Week Range $0.26 - 1.51
Shares Outstanding (Mil)126.50

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 27 40
EPS ($) -0.43 -0.03
EPS without NRI ($) -0.43 -0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}